Insmed Incorporated
INSMDrugs in Pipeline
19
Phase 3 Programs
11
Upcoming Catalysts
2
Next Catalyst
May 22, 2026
9wMarket Overview
Stock performance and key metrics
4 upcoming, 2 past
Treprostinil Palmitil Inhalation Powder Phase 3 Results Expected
Primary completion for Treprostinil Palmitil Inhalation Powder trial (NCT05649722) in Pulmonary Hypertension
Source3 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Liposomal amikacin for inhalation
Cystic Fibrosis
Treprostinil Palmitil
Pulmonary Hypertension
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Pseudomonas Aeruginosa Infection
ALIS
Mycobacterium Infections, Nontuberculous
Azithromycin
Mycobacterium Infections, Nontuberculous
LAI (Liposomal Amikacin for Inhalation) 590 mg
Mycobacterium Infections, Nontuberculous
Brensocatib 10 mg
Non-Cystic Fibrosis Bronchiectasis
rhIGF-I/rhIGFBP-3
Myotonic Dystrophy Type 1
Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension
Brensocatib 25 mg
Non-Cystic Fibrosis Bronchiectasis
LAI 590 mg
NTM Lung Infection Due to MAC
ARIKACE™
Cystic Fibrosis
Cisplatin liposomal
Osteosarcoma Metastatic
Arikayce™ 560 mg
Cystic Fibrosis
Mometasone furoate nasal spray (MFNS)
Chronic Rhinosinusitis Without Nasal Polyps
280 mg Arikayce™
Bronchiectasis
Liposomal amikacin for inhalation (LAI)
Mycobacterium Infections, Nontuberculous
Brensocatib
Hidradenitis Suppurativa
Arikayce™
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Liposomal amikacin for inhalation | Phase 3 | Cystic Fibrosis | - | - |
Treprostinil Palmitil | Phase 3 | Pulmonary Hypertension | - | - |
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Phase 3 | Pseudomonas Aeruginosa Infection | - | - |
ALIS | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
Azithromycin | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
LAI (Liposomal Amikacin for Inhalation) 590 mg | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
Brensocatib 10 mg | Phase 3 | Non-Cystic Fibrosis Bronchiectasis | - | - |
rhIGF-I/rhIGFBP-3 | Phase 3 | Myotonic Dystrophy Type 1 | - | - |
Treprostinil Palmitil Inhalation Powder | Phase 3 | Pulmonary Hypertension | - | - |
Brensocatib 25 mg | Phase 3 | Non-Cystic Fibrosis Bronchiectasis | - | - |
LAI 590 mg | Phase 3 | NTM Lung Infection Due to MAC | - | - |
ARIKACE™ | Phase 2 | Cystic Fibrosis | - | - |
Cisplatin liposomal | Phase 2 | Osteosarcoma Metastatic | - | - |
Arikayce™ 560 mg | Phase 2 | Cystic Fibrosis | - | - |
Mometasone furoate nasal spray (MFNS) | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps | - | - |
280 mg Arikayce™ | Phase 2 | Bronchiectasis | - | - |
Liposomal amikacin for inhalation (LAI) | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
Brensocatib | Phase 2 | Hidradenitis Suppurativa | - | - |
Arikayce™ | Phase 2 | Cystic Fibrosis | - | - |
Cystic Fibrosis
5 drugs in this indication
Mycobacterium Infections, Nontuberculous
4 drugs in this indication
Non-Cystic Fibrosis Bronchiectasis
2 drugs in this indication
Pulmonary Hypertension
2 drugs in this indication
NTM Lung Infection Due to MAC
1 drug in this indication
Hidradenitis Suppurativa
1 drug in this indication
Myotonic Dystrophy Type 1
1 drug in this indication
Osteosarcoma Metastatic
1 drug in this indication
Pseudomonas Aeruginosa Infection
1 drug in this indication
Bronchiectasis
1 drug in this indication
Chronic Rhinosinusitis Without Nasal Polyps
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)